Celltrion submits application to EMA for biosimilar infliximab

Celltrion Inc. (KOSDAQ:068270) submitted a regulatory application to EMA for a biosimilar version of autoimmune drug infliximab. According to EMA, this is the first application submitted for a biosimilar mAb. The product is partnered with Hospira Inc. (NYSE:HSP). Celltrion was up KrW100 to KrW36,050 on Monday, while Hospira was off $0.01 to $34.45. ...